Retinal Vein Occlusion
📧 Sign up to get email alerts when something new happens for Retinal Vein Occlusion.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-21EMA Authorised: Eylea (aflibercept) — Bayer AG
EMA authorises Eylea (aflibercept) for multiple ocular conditions including wet age-related macular degeneration and diabetic eye diseases.
-
EMA approval · 2026-08-18EMA Authorised: Vislyfa (ranibizumab) — Lupin Europe GmbH
The EMA has authorised Vislyfa (ranibizumab) by Lupin Europe GmbH for multiple retinal and diabetic eye diseases, expanding access to this a…
-
EMA approval · 2026-07-03EMA Authorised: Opuviz (aflibercept) — Samsung Bioepis NL B.V.
Aflibercept-based therapy Opuviz has been authorised in the EU for multiple ocular conditions including wet age-related macular degeneration…
-
EMA approval · 2026-07-01EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) for multiple ophthalmic conditions including wet age-related macular degeneration, macular edema, and…
-
EMA approval · 2026-06-16EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) by Celltrion Healthcare Hungary Kft. for multiple retinal diseases including wet age-related macular …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-04-24EMA Authorised: Ranluspec (ranibizumab) — Lupin Europe GmbH
EMA authorised Ranluspec (ranibizumab) from Lupin Europe GmbH. The product is indicated for several retinal conditions including wet age-rel…
-
EMA approval · 2026-04-14EMA Authorised: Pavblu (aflibercept) — Amgen Technology (Ireland) UC
EMA has authorised Pavblu (aflibercept) by Amgen Technology (Ireland) UC for multiple ocular indications including wet age-related macular d…
-
EMA approval · 2026-04-10EMA Authorised: Mynzepli (aflibercept) — Advanz Pharma Limited
The European Union has authorised Mynzepli (aflibercept) from Advanz Pharma Limited for multiple retinal diseases, including wet age-related…
-
EMA approval · 2026-03-04EMA Authorised: Eylea (aflibercept) — Bayer AG
The EMA authorised Eylea (aflibercept) from Bayer AG for multiple ocular indications, including wet age-related macular degeneration, macula…
-
EMA approval · 2026-03-03EMA Authorised: Afqlir (aflibercept) — Sandoz GmbH
The EMA authorised Afqlir (aflibercept) from Sandoz GmbH for retinal conditions including wet age-related macular degeneration, macular edem…
-
EMA approval · 2026-02-26EMA Authorised: Yesafili (aflibercept) — Biosimilar Collaborations Ireland Limited
Yesafili is an authorised aflibercept biosimilar by Biosimilar Collaborations Ireland Limited for various retinal diseases, expanding treatm…
-
EMA approval · 2026-01-19EMA Authorised: Opuviz (aflibercept) — Samsung Bioepis NL B.V.
EMA authorised Opuviz (aflibercept) by Samsung Bioepis NL B.V. for treating several retinal conditions including wet age-related macular deg…
-
EMA approval · 2025-12-10EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) from Celltrion Healthcare Hungary Kft. for multiple ocular conditions including wet age-related macul…
-
EMA approval · 2025-11-21EMA Authorised: Eiyzey (aflibercept) — Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
The EMA authorised Eiyzey (aflibercept) from Zaklady Farmaceutyczne Polpharma S.A. for multiple retinal diseases, including wet age-related …
-
FDA approval · 2025-11-19FDA Approved: EYLEA HD — Supplemental Application (Regeneron Pharmaceuticals, Inc)
The FDA approved a supplemental application for EYLEA HD (aflibercept) by Regeneron, introducing a high-dose formulation.
-
EMA approval · 2025-11-13EMA Authorised: Afiveg (aflibercept) — STADA Arzneimittel AG
The EMA has authorised Afiveg, an aflibercept product by STADA, for multiple retinal conditions including wet age-related macular degenerati…
-
FDA approval · 2025-11-12FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
The FDA approved a supplemental Biologics License Application for BYOOVIZ (ranibizumab-nuna) from Biogen, expanding regulatory clearance for…
-
EMA approval · 2025-11-12EMA Authorised: Eyluxvi (aflibercept) — Biolitec pharma Limited Zweigniederlassung Jena
EMA authorised Eyluxvi (aflibercept) from Biolitec pharma Limited Zweigniederlassung Jena for treatment of wet age-related macular degenerat…
-
EMA approval · 2025-11-07EMA Authorised: Baiama (aflibercept) — Formycon AG
EMA authorised Baiama, a biosimilar aflibercept from Formycon AG, for multiple retinal diseases including wet age-related macular degenerati…
-
EMA approval · 2025-11-07EMA Authorised: Ahzantive (aflibercept) — Formycon AG
EMA authorised Ahzantive (aflibercept) from Formycon AG for several retinal diseases including wet age-related macular degeneration and diab…
-
EMA approval · 2025-11-04EMA Authorised: Vgenfli (aflibercept) — Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
The EMA authorized Vgenfli (aflibercept) from Polpharma for multiple retinal diseases, including wet age-related macular degeneration, macul…
-
FDA approval · 2022-08-02FDA Approved: CIMERLI — Original Application (Coherus BioSciences Inc)
FDA approved CIMERLI (ranibizumab-eqrn) from Coherus as an original Biologics License Application. It is a biosimilar to ranibizumab (Lucent…
-
FDA approval · 2017-05-26FDA Approved: EYLEA — Supplemental Application (Regeneron Pharmaceuticals, Inc.)
FDA approved a supplemental application for EYLEA (aflibercept) submitted by Regeneron Pharmaceuticals, Inc. The action updates labeling and…